Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin.

Reckamp, Karen L

Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. [electronic resource] - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer Feb 2008 - 117-24 p. digital

Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

1556-1380

10.1097/JTO.0b013e3181622bef doi


Antineoplastic Combined Chemotherapy Protocols--pharmacology
Biomarkers, Tumor--blood
Cadherins--blood
Carcinoma, Non-Small-Cell Lung--drug therapy
Celecoxib
Chemokines, CC--blood
Cyclooxygenase Inhibitors--pharmacology
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm
ErbB Receptors--antagonists & inhibitors
Erlotinib Hydrochloride
Humans
Lung Neoplasms--drug therapy
Macrophage Inflammatory Proteins--blood
Matrix Metalloproteinase 9--blood
Protein Kinase Inhibitors--pharmacology
Pyrazoles--administration & dosage
Quinazolines--administration & dosage
Sulfonamides--administration & dosage
Tissue Inhibitor of Metalloproteinase-1--blood